Drug Profile
Budesonide aerosolised formulation - AstraZeneca/SkyePharma
Alternative Names: Budesonide pMDI - AstraZeneca; Pulmicort HFA; Pulmicort HFA-MDI; Pulmicort pMDILatest Information Update: 19 Dec 2021
Price :
$50
*
At a glance
- Originator AstraZeneca; SkyePharma PLC
- Developer AstraZeneca
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Market Withdrawal Asthma
Most Recent Events
- 08 Mar 2011 Production discontinued for Asthma in Austria (Inhalation)
- 08 Mar 2011 Production discontinued for Asthma in Denmark (Inhalation)
- 08 Mar 2011 Production discontinued for Asthma in Germany (Inhalation)